New Drug Development for Known and Emerging Viruses
PAYBACK Punkte
86 °P sammeln!
Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists and virologists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronavirus-2 causing the present pandemic. 'New Drug Devel...
Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades
Written by leading medicinal chemists and virologists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronavirus-2 causing the present pandemic.
'New Drug Development for Known and Emerging Viruses' describes the discovery and development process of antiviral agents for different species of viruses and their targets based on the experiences from seven human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HCMV, and HSV). It covers the properties and potential of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses.
_ Covers the entire field of antiviral drug discovery and development
_ Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2
_ Summarizes the successes of the past years in developing ground-breaking medicines against 7 major human viruses, both from the medicinal chemistry and the pharmacological angle
_ Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues
'New Drug Development for Known and Emerging Viruses' is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies.
Written by leading medicinal chemists and virologists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronavirus-2 causing the present pandemic.
'New Drug Development for Known and Emerging Viruses' describes the discovery and development process of antiviral agents for different species of viruses and their targets based on the experiences from seven human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HCMV, and HSV). It covers the properties and potential of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses.
_ Covers the entire field of antiviral drug discovery and development
_ Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2
_ Summarizes the successes of the past years in developing ground-breaking medicines against 7 major human viruses, both from the medicinal chemistry and the pharmacological angle
_ Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues
'New Drug Development for Known and Emerging Viruses' is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies.
Andere Kunden interessierten sich für
